Following this report, we totally restructured our formulary review committee. We restructured the membership. We put in guiding principles to make decisions, and evidence to be weighed to decide on whether we would or would not list a drug. Cannabis aside, all the other drugs go through the Canadian review committee. In Canada there are recommendations to list or not. We consider those recommendations. We also align with the Canadian Armed Forces. We look at what drugs they have, because when the veterans are released, especially for medical reasons, we want to make sure we have the same drugs on our formulary so there are no gaps in health care as they leave the military.
We've done a lot of work since the report of the Auditor General. It was timely and useful for us to look at those recommendations and to make important changes to the way we manage the drug program.
There have also been some product listing agreements that we're looking at so that if a drug is bought by a federal agency, all the other federal agencies have the opportunity to have the drug at the same favourable price that we've negotiated with the producers.
We've done a lot of changes to the drug program.